EX105
/ ExcelMab
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 25, 2024
A novel B7-H3 x CD3 bispecific T-cell engager for the treatment of B7-H3+ tumors.
(ASCO 2024)
- "These findings collectively indicate that EX105 has the potential to become a promising therapeutic agent for the treatment of various B7-H3 positive cancers. The first-in-human clinical trial for patients with advanced B7-H3 positive cancers is due to start."
Oncology • Solid Tumor • CD276
1 to 1
Of
1
Go to page
1